Literature DB >> 7946157

Estrogen augments the contribution of nitric oxide to blood pressure regulation in transgenic hypertensive rats expressing the mouse Ren-2 gene.

K B Brosnihan1, A Moriguchi, H Nakamoto, R H Dean, D Ganten, C M Ferrario.   

Abstract

Transgenic rats carrying the mouse Ren-2 gene (Ren-2d)27 provide a unique model to study the interplay between the renin-angiotensin system and estrogen in the pathogenesis of hypertension. In this study we measured the effects of ovariectomy and estrogen replacement on blood pressure and the contribution of vascular endothelium relaxing factor, nitric oxide, in female transgenic hypertensive rats and normotensive Sprague-Dawley (SD) rats. Both groups of animals were either ovariectomized or sham-operated at 12 weeks of age. Ovariectomized rats were treated with either 17 beta-estradiol (70 micrograms/day) or placebo for 4 weeks, whereas sham-operated rats received placebo alone. Mean arterial blood pressure measured in conscious rats directly by an arterial catheter was significantly higher in ovariectomized rats, compared with ovariectomized rats given estrogen replacement therapy for both transgenic (167 +/- 5 v 154 +/- 4 mm Hg, P < .05) and SD rats (125 +/- 4 v 113 +/- 5 mm Hg, P < .05). The contribution of endothelium-derived nitric oxide to the maintenance of blood pressure was examined by acute systemic injection of NG-monomethyl-L-arginine (L-NMMA, 10 mg/kg). L-NMMA caused a significantly greater increase in blood pressure in sham-operated transgenic as compared to SD rats (34 +/- 3 v 14 +/- 3 mm Hg, P < .05). The response in ovariectomized transgenic rats was markedly reduced (13 +/- 3 mm Hg), reaching levels that were no different from sham-operated SD rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946157     DOI: 10.1093/ajh/7.7.576

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  9 in total

1.  Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

2.  Renal NOS activity, expression, and localization in male and female spontaneously hypertensive rats.

Authors:  Jennifer C Sullivan; Jennifer L Pardieck; Kelly A Hyndman; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-04       Impact factor: 3.619

Review 3.  Evidence that the G protein-coupled membrane receptor GPR30 contributes to the cardiovascular actions of estrogen.

Authors:  Sarah H Lindsey; Mark C Chappell
Journal:  Gend Med       Date:  2011-12

4.  Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.

Authors:  Norihito Moniwa; Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2012-01-05

Review 5.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

6.  Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring.

Authors:  Norma B Ojeda; Daniela Grigore; Elliott B Robertson; Barbara T Alexander
Journal:  Hypertension       Date:  2007-08-27       Impact factor: 10.190

7.  Effects of oestrogen replacement on steady and pulsatile haemodynamics in ovariectomized rats.

Authors:  Kwok-Keung Lam; Cheng-Tao Hu; Tein-Yuan Ou; Mao-Hsiung Yen; Hsing-I Chen
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

8.  Chronic treatment with atrial natriuretic peptide in spontaneously hypertensive rats: beneficial renal effects and sex differences.

Authors:  Mariana Romero; Carolina Caniffi; Gonzalo Bouchet; María A Costa; Rosana Elesgaray; Cristina Arranz; Analía L Tomat
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

9.  Sex differences in the beneficial cardiac effects of chronic treatment with atrial natriuretic Peptide in spontaneously hypertensive rats.

Authors:  Mariana Romero; Carolina Caniffi; Gonzalo Bouchet; Rosana Elesgaray; Myriam Mac Laughlin; Analía Tomat; Cristina Arranz; Maria A Costa
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.